Evidence map›Paper›PMID 40323371›Full record

ArticleRheumatology and therapy2025

Correction: Safety and Efficacy of Bimekizumab in Patients with Psoriatic Arthritis: 2-Year Results from Two Phase 3 Studies.

Philip J Mease, Joseph F Merola, Yoshiya Tanaka, Laure Gossec, Iain B McInnes, Christopher T Ritchlin, Robert B M Landewé, Akihiko Asahina, Barbara Ink, Andrea Heinrichs and 4 more

Abstract readPublished Erratum
PubMed Full text at PMC Publisher
In one paragraph

Article in Rheumatology and therapy, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors.

Philip J MeaseDepartment of Rheumatology, Providence-Swedish Medical Center and University of Washington, Seattle, WA, USA. pmease@philipmease.com.ORCID http://orcid.org/0000-0002-6620-0457
Joseph F MerolaHarvard Medical School, Brigham and Women's Hospital, Boston, MA, USA.ORCID http://orcid.org/0000-0001-6514-4353
Yoshiya TanakaThe First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan.ORCID http://orcid.org/0000-0002-0807-7139
Laure GossecSorbonne Université, INSERM, Institut Pierre Louis d'Epidémiologie et de Santé Publique, Paris, France.ORCID http://orcid.org/0000-0002-4528-310X
Iain B McInnesCollege of Medical Veterinary and Life Sciences, University of Glasgow, Glasgow, UK.ORCID http://orcid.org/0000-0002-6462-4280
Christopher T RitchlinAllergy, Immunology & Rheumatology Division, University of Rochester Medical School, Rochester, NY, USA.ORCID http://orcid.org/0000-0002-2602-1219
Robert B M LandewéAmsterdam Rheumatology & Clinical Immunology Center, Amsterdam, and Zuyderland MC, Heerlen, The Netherlands.ORCID http://orcid.org/0000-0002-0577-6620
Akihiko AsahinaDepartment of Dermatology, The Jikei University School of Medicine, Tokyo, Japan.
Barbara InkUCB Pharma, Slough, UK.
Andrea HeinrichsUCB Biosciences GmbH, Monheim, Germany.
Rajan BajracharyaUCB Pharma, Slough, UK.
Vishvesh ShendeUCB Pharma, Slough, UK.
Jason CoarseUCB Pharma, Morrisville, NC, USA.
Laura C CoatesNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Diseases, Oxford University Hospitals NHS Trust, University of Oxford and Oxford Biomedical Research Centre, Oxford, UK.ORCID http://orcid.org/0000-0002-4756-663X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Identifiers

PMID40323371
PMCPMC12084428

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.